戻る Agenda
Future of PharmaTech
Session Chair(s)
Patrick Brady, PHARMD
Global Head, Therapeutic Innovation & Regulatory Science
IQVIA, United States
What is PharmaTech? How is the pharmaceutical and biotech industry evolving with new technologies, such as artifical intelligence (AI) and block chain? How will the business model be impacted? Are there lessons learned from other industries?
This DIAmond session will examine how innovative technologies in drug development are impacting the pharmaceutical and biotech industry.
Learning Objective : Define the concept of PharmaTech and describe it's impact on new technologies and business models; Identify how the pharmaceutical and biotech industry will be impacted by innovative technologies, such as artificial intelligence, in drug development.
Speaker(s)
Panelist
David Meyers
Microsoft, United States
National Director Life Sciences, US Health and Life Sciences
Panelist
Dina Katabi, PHD, MS
Massachusetts Institute of Technology (MIT), United States
Andrew and Erna Viterbi Professor of Electrical Engineering and Computer Science
Panelist
Sudip Parikh, PHD
American Association for the Advancement of Science (AAAS), United States
Chief Executive Officer and Executive Publisher, Science Journals
Panelist
Henry "Skip" Francis, MD
FDA/CDER/OTS/IO, United States